{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:14:19Z","timestamp":1788779659522,"version":"build-2803163510"},"reference-count":20,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T00:00:00Z","timestamp":1762041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Korean Association for the Study of Intestinal Diseases"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Therapeutic goals for ulcerative colitis (UC) have expanded beyond symptom control to include mucosal and histological healing. However, the long-term prognostic value of achieving both targets remains uncertain, particularly in Asian populations. This study aimed to evaluate long-term outcomes and relapse predictors in patients with UC who achieved both endoscopic and histologic remission. Materials and Methods: This prospective observational study consecutively enrolled adults with clinically inactive UC who attained endoscopic remission (Mayo endoscopic subscore = 0) and histologic remission (Nancy index \u22641) between June 2014 and May 2018. Demographic, clinical, and laboratory data\u2014including fecal calprotectin\u2014were collected. Clinical relapse was defined as a Mayo score increase &gt;3 or initiation of systemic corticosteroids or biologics. Patients were followed longitudinally for a median of 55 months (minimum 12 months), and relapse risk was evaluated using Kaplan\u2013Meier and univariate Cox regression analyses. Results: A total of 41 patients were included (mean age 54 \u00b1 14 years; 56% male). The median follow-up was 54 months (range 17\u201378). Ten patients (24.4%) relapsed during follow-up, with cumulative relapse rates of 9.8%, 10.3%, 15.8%, and 24.1% at 12, 24, 36, and 48 months, respectively. Kaplan\u2013Meier analyses demonstrated significantly higher relapse in patients with non-E1 disease (E2 + E3, p = 0.021), immunomodulator use (p = 0.008), and biologics use (p = 0.007). In univariate Cox regression, immunomodulator (HR 4.7, 95% CI 1.3\u201316.4, p = 0.02) and biologics use (HR 4.9, 95% CI 1.4\u201317.5, p = 0.01) were significant predictors of relapse, whereas disease extent showed only a non-significant trend with wide CIs. Baseline fecal calprotectin was higher in the relapse group (182 \u00b1 370 \u03bcg\/g vs. 108 \u00b1 164 \u03bcg\/g) but was not statistically significant. Conclusions: Approximately one-quarter of UC patients who achieved dual remission relapsed within 4 years. These findings highlight the limitations of using dual remission as the sole therapeutic endpoint and underscore the need for additional prognostic factors. High-risk subgroups\u2014such as those with extensive disease or prior exposure to advanced therapies\u2014may require closer monitoring and individualized strategies. Future multicenter studies integrating clinical, endoscopic, histologic, and biomarker data are needed to refine relapse prediction.<\/jats:p>","DOI":"10.3390\/medicina61111968","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T13:55:22Z","timestamp":1762178122000},"page":"1968","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Long-Term Clinical Outcomes of Ulcerative Colitis with Concurrent Endoscopic and Histologic Remission"],"prefix":"10.3390","volume":"61","author":[{"given":"Ji Min","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, St. Vincent\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 16247, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang-Moon","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, St. Vincent\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 16247, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Bum","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, St. Vincent\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 16247, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Han","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Hospital Pathology, St. Vincent\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 16247, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1136\/gutjnl-2012-302830","article-title":"Mucosal healing in inflammatory bowel diseases: A systematic review","volume":"61","author":"Neurath","year":"2012","journal-title":"Gut"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1053\/j.gastro.2011.06.054","article-title":"Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis","volume":"141","author":"Colombel","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.cgh.2017.02.016","article-title":"Histologic Normalization Occurs in Ulcerative Colitis and Is Associated with Improved Clinical Outcomes","volume":"15","author":"Christensen","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1097\/MIB.0b013e318280e75f","article-title":"Correlation between the endoscopic and histologic score in assessing the activity of ulcerative colitis","volume":"19","author":"Lemmens","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/gutjnl-2015-309598","article-title":"Beyond endoscopic mucosal healing in UC: Histological remission better predicts corticosteroid use and hospitalisation over 6\u2005years of follow-up","volume":"65","author":"Bryant","year":"2016","journal-title":"Gut"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.cgh.2013.07.022","article-title":"Histologic remission: The ultimate therapeutic goal in ulcerative colitis?","volume":"12","author":"Bressenot","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.gie.2018.08.018","article-title":"The emerging role of histologic disease activity assessment in ulcerative colitis","volume":"88","author":"Pai","year":"2018","journal-title":"Gastrointest. Endosc."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"591","DOI":"10.5009\/gnl220202","article-title":"Oral Sulfate Solution Is as Effective as Polyethylene Glycol with Ascorbic Acid in a Split Method for Bowel Preparation in Patients with Inactive Ulcerative Colitis: A Randomized, Multicenter, and Single-Blind Clinical Trial","volume":"17","author":"Lee","year":"2023","journal-title":"Gut Liver"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/01.MIB.0000195391.49762.89","article-title":"Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: Prevalence and impact on health","volume":"12","author":"Farrokhyar","year":"2006","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000518131","article-title":"Assessment of Endoscopic Disease Activity in Ulcerative Colitis: Is Simplicity the Ultimate Sophistication?","volume":"7","author":"Sharara","year":"2022","journal-title":"Inflamm. Intest. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/gutjnl-2015-310187","article-title":"Development and validation of the Nancy histological index for UC","volume":"66","author":"Salleron","year":"2017","journal-title":"Gut"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4166\/kjg.2017.69.1.1","article-title":"Second Korean Guideline for the Management of Ulcerative Colitis","volume":"69","author":"Choi","year":"2017","journal-title":"Korean J. Gastroenterol. Taehan Sohwagi Hakhoe Chi"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.crohns.2013.06.001","article-title":"European consensus on the histopathology of inflammatory bowel disease","volume":"7","author":"Magro","year":"2013","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1053\/j.gastro.2020.06.043","article-title":"Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients with Ulcerative Colitis: A Systematic Review and Meta-Analysis","volume":"159","author":"Yoon","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.dld.2017.09.130","article-title":"Is histologic remission in ulcerative colitis ready for prime time?","volume":"49","author":"Guardiola","year":"2017","journal-title":"Dig. Liver Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/ibd\/izad159","article-title":"Disease Clearance as a New Outcome in Ulcerative Colitis: A Systematic Review and Expert Consensus","volume":"30","author":"Magro","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/ueg2.12288","article-title":"Ulcerative colitis: Impact of early disease clearance on long-term outcomes\u2014A multicenter cohort study","volume":"10","author":"Fiorino","year":"2022","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1097\/MIB.0000000000000736","article-title":"Fecal Calprotectin Predicts Relapse and Histological Mucosal Healing in Ulcerative Colitis","volume":"22","author":"Theede","year":"2016","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"10291","DOI":"10.1038\/s41467-024-54797-8","article-title":"Multi-biome analysis identifies distinct gut microbial signatures and their crosstalk in ulcerative colitis and Crohn\u2019s disease","volume":"15","author":"Akiyama","year":"2024","journal-title":"Nat. Commun."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/11\/1968\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T14:45:55Z","timestamp":1762181155000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/11\/1968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,2]]},"references-count":20,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["medicina61111968"],"URL":"https:\/\/doi.org\/10.3390\/medicina61111968","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,2]]}}}